Wells Fargo & Company Reiterates “Equal Weight” Rating for Cooper Companies (NASDAQ:COO)

Cooper Companies (NASDAQ:COO)‘s stock had its “equal weight” rating reaffirmed by investment analysts at Wells Fargo & Company in a report issued on Thursday, MarketBeat.com reports. They currently have a $72.00 price target on the medical device company’s stock. Wells Fargo & Company‘s price target points to a potential downside of 0.15% from the company’s current price.

A number of other brokerages also recently weighed in on COO. BNP Paribas Exane upgraded shares of Cooper Companies from a “neutral” rating to an “outperform” rating and set a $92.00 target price on the stock in a report on Tuesday, July 22nd. The Goldman Sachs Group set a $64.00 price objective on Cooper Companies and gave the company a “sell” rating in a research report on Wednesday, October 1st. Barclays assumed coverage on Cooper Companies in a report on Monday, October 13th. They set an “overweight” rating and a $85.00 target price on the stock. Needham & Company LLC restated a “buy” rating and set a $94.00 target price on shares of Cooper Companies in a research note on Thursday, August 28th. Finally, Mizuho cut their price objective on shares of Cooper Companies from $105.00 to $90.00 and set an “outperform” rating for the company in a research report on Wednesday, July 16th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Cooper Companies currently has a consensus rating of “Moderate Buy” and a consensus target price of $84.77.

Cooper Companies Stock Down 0.5%

Shares of Cooper Companies stock traded down $0.39 during trading on Thursday, reaching $72.11. The stock had a trading volume of 158,821 shares, compared to its average volume of 2,334,304. The company has a current ratio of 2.12, a quick ratio of 1.24 and a debt-to-equity ratio of 0.29. The company has a market capitalization of $14.34 billion, a price-to-earnings ratio of 35.50, a P/E/G ratio of 1.83 and a beta of 1.02. Cooper Companies has a 52 week low of $61.78 and a 52 week high of $106.63. The stock has a fifty day moving average price of $69.54 and a two-hundred day moving average price of $72.44.

Cooper Companies (NASDAQ:COO) last released its earnings results on Wednesday, August 27th. The medical device company reported $1.10 earnings per share for the quarter, beating analysts’ consensus estimates of $1.07 by $0.03. The business had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.06 billion. Cooper Companies had a net margin of 10.08% and a return on equity of 9.82%. The firm’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.96 earnings per share. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. Sell-side analysts predict that Cooper Companies will post 3.98 EPS for the current fiscal year.

Cooper Companies declared that its Board of Directors has initiated a stock buyback program on Wednesday, September 17th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical device company to repurchase up to 15.4% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its shares are undervalued.

Insiders Place Their Bets

In other Cooper Companies news, COO Gerard H. Warner III acquired 1,450 shares of Cooper Companies stock in a transaction on Friday, September 5th. The stock was purchased at an average price of $69.23 per share, for a total transaction of $100,383.50. Following the purchase, the chief operating officer directly owned 18,319 shares of the company’s stock, valued at $1,268,224.37. This trade represents a 8.60% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Daniel G. Mcbride purchased 3,000 shares of the stock in a transaction dated Tuesday, September 2nd. The stock was acquired at an average cost of $65.04 per share, for a total transaction of $195,120.00. Following the transaction, the chief operating officer owned 63,120 shares of the company’s stock, valued at approximately $4,105,324.80. This trade represents a 4.99% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased a total of 17,975 shares of company stock valued at $1,216,346 over the last three months. Insiders own 1.98% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of COO. Zions Bancorporation National Association UT bought a new position in shares of Cooper Companies in the 1st quarter worth about $33,000. GKV Capital Management Co. Inc. purchased a new position in Cooper Companies during the first quarter valued at $40,000. J.Safra Asset Management Corp boosted its holdings in Cooper Companies by 204.8% in the second quarter. J.Safra Asset Management Corp now owns 506 shares of the medical device company’s stock worth $36,000 after acquiring an additional 340 shares in the last quarter. CYBER HORNET ETFs LLC purchased a new position in shares of Cooper Companies in the 2nd quarter worth about $36,000. Finally, MUFG Securities EMEA plc bought a new stake in Cooper Companies during the 2nd quarter valued at about $42,000. Hedge funds and other institutional investors own 24.39% of the company’s stock.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.